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Intrathecal (IT) chemotherapy can be given to patients with
acute leukemia post hematopoietic stem cell transplant
(HSCT) in an attempt to prevent relapse in the central
nervous system (CNS). We performed a retrospective
analysis of 166 patients with acute leukemia who under-
went ﬁrst HSCT at Memorial Sloan-Kettering Cancer Center
between 1999 and 2013. Patients who were not eligible for
post HSCT IT prophylaxis due to graft-versus-host disease
or acute transplant related complications were excluded
from the analysis. Indication for HSCT included acute
lymphoblastic leukemia (ALL) (n¼115), acute myeloid leu-
kemia (n¼45) or acute biphenotypic leukemia (n¼6). The
median age of patients was 10.7 years (range 0.6-27.5).
Disease status at transplant included CR1 (38%), CR2 (44%)
and not in remission (4%). Donor grafts underwent ex vivo T
cell depletion in 67% (110) of patients, and 71.6% (116) of
patients received their graft from an unrelated donor.
Conditioning therapy included TBI in 76% of cases. Patients
with a history of CNS disease (36%) were included in this
analysis; these patients received CNS radiation either dur-
ing induction therapy or as a boost prior HSCT. Monthly
post-transplant IT prophylaxis was administered to 71% of
patients, starting at 2 months post HSCT. Prophylaxis con-
sisted of IT cytarabine +/- hydrocortisone, with patients
with no prior CNS disease receiving 5 doses post HSCT and
those with previous CNS disease receiving 11 doses. The
rate of overall relapse at 2 years was 33.2% for the entire
cohort, with a CNS relapse rate of 5.4%. The CNS relapse rate
at 2 years for patients with ALL was 7.1%, and only 1 patient
with AML developed CNS relapse. In subset analysis, pa-
tients with ALL who received IT prophylaxis post HSCT had
a signiﬁcantly lower rate of CNS relapse compared to those
that did not (4.4% vs 17.3%, P ¼ 0.04). Our study demon-
strates that monthly IT prophylaxis with cytarabine +/-
hydrocortisone post HSCT may be beneﬁcial for patients
with acute lymphoblastic leukemia in the prevention of
CNS relapse.
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Mixed Chimerism and Graft Loss in Pediatric Recipients
of an Alemtuzumab-Based Reduced-Intensity
Conditioning Regimen for Nonmalignant Disease
Benjamin Oshrine, Timothy Olson, Nancy Bunin. Children’s
Hospital of Philadelphia, Philadelphia, PA
Reduced-intensity conditioning (RIC) regimens are increas-
ingly used to reduce transplant-related mortality (TRM) for
pediatric patients (pts) undergoing hematopoietic cell trans-
plantation (HCT) for nonmalignant diseases. However, these
pts are at increased risk for post-transplant mixed donor/
recipient chimerism (MC) and/or primary and secondary graft
failure (GF). Intervention with donor lymphocytes (DLI) orsecond transplants may be necessary, but there is limited in-
formation about timing and results of intervention. We
retrospectively evaluated 31 consecutive pediatric recipients
of an alemtuzumab-based RIC HCT at the Children’s Hospital
of Philadelphia from May 2007 to December 2012 to deter-
mine the incidence of MC and GF, and timing of interventions.
All pts received alemtuzumab (Campath) with either ﬂudar-
abine (150mg/m2)/melphalan (140 mg/m2) (n¼30) or ﬂudar-
abine/busulfan (n¼1). The timing of Campath differed
according to disease. Pts with hematologic disorders and IPEX
received Campath beginning day -21 or -22. Pts with hemo-
phagocytic lymphohistiocytosis (HLH) received proximal
(N¼8) or intermediate (n¼2 ) Campath starting at day -9 or
-13, respectively. Diagnoses included HLH in 10 pts, hemo-
globinopathy in 8 pts, primary immunodeﬁciency in 8 pts, and
bone marrow failure in 5 pts. All grafts were unmanipulated
bone marrow from matched sibling donors (45%), matched
unrelated donors (52%) or mismatched related donor (3%).
Donor chimerism was evaluated using polymerase chain re-
action of microsatellite markers/short tandem repeats at
regular intervals post-transplant. Four pts died of TRM (n¼3)
or early disease progression (n¼1) and were not included in
the analysis. Of the 27 surviving pts, 18 (66.7%) displayed MC
(donor chimerism <100%) on at least one occasion, with 12
(44.4%) reaching a nadir MC level <80%. Two pts with
MC80% experienced recurrent disease, one with HLH and
one with auto-immune syndrome. Of the 12 pts with nadir
MC<80%, 6 received DLI with 2 subsequent GFs. Of the
remaining 6 pts who did not receive DLI, there were also 2
GFs. The overall incidence of GF/recurrence was 22.2% (6/27).
Within the HLH group 7/7 surviving pts developedMC, with 5
(71.4%) reaching a nadir <80%. Despite DLI/boost in all 5 of
these pts, 2 progressed to GF. The incidence of GF/recurrence
in the surviving HLH pts was 42.9% (3/7) By contrast, in the
non-HLH pts, only 11 of 20 (55.0%) surviving pts developed
MC with 7 (35.0%) reaching a nadir<80%. Of these 7 with
MC<80%, 2 progressed to GF for an overall incidence of GF/
recurrence of disease of 15% (3/20). In summary, we observed
a high incidence of MC and GF in recipients of Campath-based
RIC, particularly in HLH pts. The role for DLI/boost in pre-
venting GF in pts receiving RIC HCT for non-malignant disease
who experience low/falling MC requires further study.93
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Viral infections are associated with signiﬁcant morbidity and
mortality following AlloHCT. There are no established
guidelines for the frequency of viral monitoring and only a
few studies in children have analyzed the impact of viremia
on AlloHCT related outcomes. In 2008, our center created a
standard operating procedure of prospective PCR monitoring
for CMV, EBV and ADV prior to AlloHCT and then weekly for
180 days post AlloHCT.
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EBV and ADV copies/ml were 600, 1000 and 1000,
respectively. Viremia was deﬁned as peri-AlloHCT (d0 -
d+14), early viremia (d15 - d+98) and late viremia (d+99 -
d+180). From 2008- 2012, 100 consecutive children (median
age, 8 yrs; range 0.25-22 yrs; 35F/ 65M) undergoing
AlloHSCT for malignant (n¼53) and nonmalignant (n¼47)
disorders, were monitored. Donor sources included:
matched family donor (n¼ 42, 42%), matched unrelated do-
nors (n¼28, 28%) and unrelated cord bloods (n¼20, 20%).
Patients were conditioned with either myeloablative [MA]
(n¼43, 43%), reduced toxicity [RT] (n¼35, 35%), or reduced
intensity [RI] (n¼22, 22%) regimens. Additionally, a total of
79 patients (79%) received serotherapy with alemtuzumab
(n¼48, 48%) or rabbit-Anti-thymocyte globulin [r-ATG]
(n¼31, 31%).
The incidence of pre-AlloHCT viremia was 8%. The incidence
of post-AlloHCT single viremia, multiple viremia and viral
disease was 41, 15 and 22% respectively. The incidence of
peri-AlloHCT, early and late viremia was CMV: 5%, 22.2% and
6.6%; EBV: 1%, 9.1% and 1.1%; ADV: 5%, 10.1%, and 6.6%,
respectively. Viremia was noted in 36/80 (45%) of patients
who received serotherapy vs. 5/20 (25%) who did not receive
serotherapy (Chi-square test p¼0.1). Days for neutrophil,
platelet engraftment, incidence of graft failure and aGVHD
were not statistically signiﬁcant between patients with and
without viremia.
We performed univariate and multivariate analysis for risk
factors associated with viremia: age, sex, donor, stem cell
source, graft failure, CMV risk status, alemtuzumab, r-ATG,
malignant vs. non-malignant disease, MA vs. RT vs. RI regi-
mens, absolute neutrophil and lymphocyte count at day +30.
Only CMV risk status (p¼.0002) and pre-AlloHCT viremia (p¼
0.0095) were signiﬁcant on multivariate analysis. Among
patients with viremia vs. those without viremia, 1yr trans-
plant related mortality (TRM) and all-cause mortality was
23.7% vs. 16.7 (p¼.4) and 36.8% vs. 18.5% (p¼0.04),
respectively.
Among patients with viremia vs. without viremia, the me-
dian length of initial hospitalization (LOH) vs. LOH in the ﬁrst
180 days were 44 days (9-144) vs. 35(19-180) (p¼0.02) and
91 days ( 9-165) vs. 59 days (19-180), (p¼0.05) respectively.
Post-AlloHSCT viremia remains a signiﬁcant problem and
results in a signiﬁcantly longer LOH. Potentially due to
weekly monitoring the TRM was not signiﬁcantly higher in
patients with viremia.94
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The outcome of newly diagnosed children, adolescents and
young adults (CAYA) with lymphoma has improved signiﬁ-
cantly over the past 30 years. However, for patients with
poor-risk recurrent/refractory lymphoma, outcomes are still
dismal (<30%) despite intensive salvage therapy with mye-
loablative conditioning and autologous stem cell trans-
plantation (MAC AutoSCT) [Bradley/ Cairo, et al. BMT, 2008].
To address this problem, we designed a stem cell trans-
plantation approach to maximize an allogeneic graft versus
lymphoma effect in the setting of low disease burden (Cairo
et al. BBMT, 2013). We conducted a multi-center prospective
study of MAC-AutoSCT, followed by a reduced intensity
conditioning and allogeneic hematopoietic stem cell trans-
plant (RIC-AlloHSCT) in selected poor-risk CAYA, with re-
fractory or recurrent HL and NHL. Eligible patients with HD
had primary induction failure, early relapse (<12 months off
therapy, excluding patients with no prior therapy or radia-
tion only), or late relapse (>12 months off therapy, limited to
patients with stage III/IV disease and/or B symptoms at
relapse). Eligible patients with NHL had primary induction
failure or were in ﬁrst, second, or third relapse. Conditioning
for MAC-AutoSCT consisted of carmustine/etoposide/cyclo-
phosphamide (Harris/Cairo et al. BBMT, 2011). The RIC
regimen prior to AlloHSCT consisted of busulfan/ﬂudarabine
(Satwani/Cairo et al. BBMT, 2013). Thirty patients (16 HL and
14 NHL), median age of 16yrs and median follow-up of 5yrs,
were entered on study. Twenty three patients completed
both MAC-AutoSCT and RIC-AlloHSCT. Allogeneic sources
included unrelated cord blood (n¼9), unrelated donor (n¼8)
and matched sibling donor (n¼6). Following RIC-AlloHSCT
(n¼23), the incidence of grade II-IV aGvHD was 21.74% and
the probability of cGvHD was 13%. The incidence of trans-
plant related mortality following RIC-AlloHSCT was 12%. The
10 year event free survival (EFS) following sequential MAC-
AutoSCT and RIC-AlloHSCT (n¼23) was 64.0% (95% CI: 46.7%-
87.7%); EFS for patients with HL and NHL was 59.8% (95% CI:
37.8%-94.7%) and 70% (95%CI: 46.7%-100%) (p¼0.613),
respectively. Comparing primary refractory and relapsed
lymphoma patients undergoing tandem transplant, the 10
year EFS for patients with refractory disease vs. relapse
with stage III-IV disease vs. relapse with stage II disease was
71% vs. 60% vs. 66%, respectively. In summary, this novel
approach ofMAC-AutoSCT followed by RIC-AlloHSCT in CAYA
patients with poor risk lymphoma is feasible and safe. The
long-term EFS with this approach is encouraging considering
the poor-risk patient characteristics and the use of unrelated
donors for RIC-AlloHSCT in the majority of cases.95
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